Home » Farmaceutica, Aleotti (Menarini): “Italians competitive despite their size”

Farmaceutica, Aleotti (Menarini): “Italians competitive despite their size”

by admin

(beraking latest news Salute) – “None of the Italian companies is comparable in size, for example, to those of the companies that produce anti-Covid vaccines today. But their research and development is extremely intense”. This was explained by Lucia Aleotti, shareholder and board member of Menarini, speaking at the online Talk Sanità, organized by RCS Academy, on the theme ‘Strategies for reforming the system and winning the pandemic’.

Aleotti recalled Menarini’s partnership with the Toscana Life Sciences Foundation, a Foundation that “carried out the research for the new anti-Covid monoclonal antibody and that sought Menarini as a company capable of fine-tuning the production process and production on large scale of a biopharmaceutical molecule. And it found Menarini ready because the company has been working for years on monoclonal antibodies for the treatment of tumors “. But, added Aleotti, in Italy there are many cases of this type: “we can mention Chiesi’s excellence in respiratory diseases. Or Dompé, who has developed a drug for the treatment of a biotechnological ocular disease, based on the studies of the Nobel laureate Rita Levi Montalcini, registered and welcomed with the ‘red carpets’ by the American regulatory authority. An all-Italian invention and production “.

Therefore, “although the size of the pharmaceutical sector with Italian capital is not comparable to that of the big international companies, the dynamism is extreme. And there are even smaller companies from which very interesting discoveries often emerge”, he concluded.

COPYRIGHT today © breaking latest news

See also  Can physical activity help prevent prostate cancer?

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy